Table 1.

Effects of antidepressants on K⁺ channels.

K+ channels	Subtypes	Direct modulation	Modulation of expression and vesicular delivery
Kv	Kv1	Fluoxetine inhibition on Kv1.1, Kv1.3, Kv1.4 and Kv1.5 [29, 30, 32]; Inhibition of fluoxetine, dapoxetine, citalopram, sertraline, paroxetine and fluvoxamine on Kv1.5 [31, 33–37]; Ketamine inhibition on Kv1 [39] and Kv1.5 [40]	–
	Kv2	Inhibition of fluoxetine, amoxapine, citalopram and retigabine on Kv2.1 [48, 52–54]	Fluoxetine downregulation on Kv2.1 [47]
	Kv4	Inhibition of imipramine, amitriptyline, mianserine, maprotiline, and trazodone on Kv4.2 and Kv4.3 [73] Inhibition of fluoxetine, dapoxetine and duloxetine on Kv4.3 [70–72]	–
	Kv7	Retigabine activation on Kv7.2/7.3 [10, 56]	–
Kir	Kir4.1	Inhibition of SSRIs and TCAs on Kir4.1 (see the review by Ohno et al. [87]) Inhibition of Lys05 on Kir4.1 [88]	Ketamine inhibition of Kir4.1 vesicular delivery [91]
	GIRK	Inhibition of fluoxetine, paroxetine, imipramine, desipramine, amitriptyline, nortriptyline, clomipramine, maprotiline, citalopram, atomoxetine, reboxetine, sertraline, duloxetine, and amoxapine on GIRK [98–102]	–
	KATP	Fluoxetine inhibition on KATP [23, 117]	–
K2P	TASK	Fluoxetine inhibition on TASK-3 [125]	–
	TREK	Inhibition of fluoxetine, norfluoxetine, paroxetine and citalopram on TREK-1 and TREK-2 (see the review by Djillani et al. [22])	–